Keystone EC, et al. - The goal of this inquiry was to examine the impact of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). Findings demonstrated that compared with placebo and adalimumab, baricitinib afforded significantly greater improvement in most PROs, including physical function morning joint stiffness (MJS), pain, fatigue and quality of life. Until the end of the study (week 52), the improvement was maintained.